Exploration of the System-Level Mechanisms of the Herbal Drug FDY003 for Pancreatic Cancer Treatment: A Network Pharmacological Investigation

• Published in: Evidence-based complementary and alternative medicine Vol. 2022; pp. 7160209 - 16
• Main Authors: Lee, Ho-Sung, Lee, In-Hee, Kang, Kyungrae, Park, Sang-In, Jung, Minho, Yang, Seung Gu, Kwon, Tae-Wook, Lee, Dae-Yeon
• Format: Journal Article
• Language: English
• Published: United States Hindawi 2022; Hindawi Limited
• Subjects: AKT protein; Bioavailability; Cancer therapies; Cell cycle; Cell death; Cell survival; Chinese medicine; Drugs; Forkhead protein; Gene expression; Gene set enrichment analysis; Genomes; Herbal medicine; MAP kinase; Pancreatic cancer; Permeability; Pharmacology; Pheochromocytoma cells; Phytochemicals; Proteins; Survival analysis; United States > US
• ISSN: 1741-427X; 1741-4288
• DOI: 10.1155/2022/7160209

Pancreatic cancer (PC) is the most lethal cancer with the lowest survival rate globally. Although the prescription of herbal drugs against PC is gaining increasing attention, their polypharmacological therapeutic mechanisms are yet to be fully understood. Based on network pharmacology, we explored the anti-PC properties and system-level mechanisms of the herbal drug FDY003. FDY003 decreased the viability of human PC cells and strengthened their chemosensitivity. Network pharmacological analysis of FDY003 indicated the presence of 16 active phytochemical components and 123 PC-related pharmacological targets. Functional enrichment analysis revealed that the PC-related targets of FDY003 participate in the regulation of cell growth and proliferation, cell cycle process, cell survival, and cell death. In addition, FDY003 was shown to target diverse key pathways associated with PC pathophysiology, namely, the PIK3-Akt, MAPK, FoxO, focal adhesion, TNF, p53, HIF-1, and Ras pathways. Our network pharmacological findings advance the mechanistic understanding of the anti-PC properties of FDY003 from a system perspective.